Cabaletta Bio, INC

Cabaletta Bio announced second quarter 2026 financial results, detailing progress in its rese-cel clinical development program for autoimmune diseases and providing updates on manufacturing partnerships.

Cabaletta Bio, Inc. announced at its Annual Meeting of Stockholders the approval to increase authorized common stock from 300 million to 600 million shares.

Cabaletta Bio announced new clinical data for its rese-cel therapy across multiple autoimmune diseases, highlighting encouraging early findings for preconditioning-free lupus treatment and strong results in myositis and systemic sclerosis.

Cabaletta Bio announced first quarter 2026 financial results, highlighting progress in its rese-cel clinical trials and a new commercial supply agreement with Cellares.

Cabaletta Bio announced new clinical and translational data for rese-cel, showcasing preconditioning-free treatment and automated manufacturing advancements.

Cabaletta Bio announced the pricing of an underwritten offering of 51,725,000 shares of common stock, raising approximately $150 million in gross proceeds.

Cabaletta Bio reports increased R&D expenses and continued net losses, highlighting substantial doubt about its ability to continue as a going concern and the need for significant future financing.

Cabaletta Bio, Inc. reported its first quarter 2026 financial results, detailing increased research and development expenses and a net loss, while highlighting progress in its clinical-stage pipeline for autoimmune diseases.

Cabaletta Bio reported increased net losses and significant R&D expenses in Q3 2025, while advancing multiple rese-cel clinical trials and securing additional financing to extend its cash runway into H2 2026.

Cabaletta Bio reports increased R&D spend and net losses, fueled by promising clinical data for its lead CAR T candidate rese-cel and a significant capital raise.

Cabaletta Bio reports its financial results for the first quarter of 2025, highlighting progress in its clinical programs and strategic initiatives.

Cabaletta Bio's Q3 2024 report details financial results, clinical trial progress, and updates on manufacturing and collaborations.

Cabaletta Bio progresses its lead CAR T therapy, rese-cel, into registrational trials for autoimmune diseases while reporting significant losses and a need for further funding.

Cabaletta Bio's 10-K filing details the company's financial results for 2024 and highlights clinical advancements in its engineered T cell therapies for autoimmune diseases.

Cabaletta Bio's 10-K filing outlines its capital structure, including voting and non-voting common stock, preferred stock, pre-funded warrants, and registration rights, while also detailing regulatory and anti-takeover measures.

Director Shawn Tomasello was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Director Mark Simon was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Director Richard C. Henriques Jr. was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Director Catherine Bollard was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Director Scott C. Brun was granted 22,000 stock options in Cabaletta Bio, Inc. as part of standard equity compensation.

Cabaletta Bio's Chief Business Officer, Arun Das, was granted 175,000 stock options with a $3.3 exercise price, vesting over several years.

Cabaletta Bio, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to elect directors, ratify auditors, and vote on key corporate actions including a significant increase in authorized shares.

Cabaletta Bio is holding its 2025 Annual Meeting of Stockholders on June 9, 2025, to vote on key proposals including director elections and increasing authorized shares.

Cabaletta Bio, Inc. will hold its annual stockholders meeting on June 3, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Cabaletta Bio announces its 2024 Annual Meeting of Stockholders to be held virtually on June 3, 2024, featuring proposals for director elections and ratification of the company's independent auditor.

Cabaletta Bio, Inc. has disclosed that Cormorant Asset Management, LP, along with Bihua Chen, now beneficially owns 5.95% of the company's common stock, primarily through the exercise of warrants.

Bain Capital Life Sciences Opportunities III, L.P. has disclosed a beneficial ownership of 9.99% in Cabaletta Bio, Inc., primarily through warrants and common stock, subject to a beneficial ownership blocker.

Adage Capital Management, L.P. has reported a beneficial ownership of 8.43% in Cabaletta Bio, Inc., including shares issuable upon warrant exercise.

Norges Bank has reported beneficial ownership of 5.38% of Cabaletta Bio, Inc.'s common stock as of June 30, 2026, classifying itself as an investment adviser.

Vanguard Capital Management has reported beneficial ownership of over 8.29 million shares, representing 5.08% of Cabaletta Bio Inc.'s common stock as of June 30, 2026.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 1.3% of Cabaletta Bio, Inc.'s common stock as of June 30, 2026.